SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF
An adjuvant formulation includes a monophosphoryl Lipid A (MPLA) analogue, a Pam3CSK4 analogue, or a muramyldipeptide (MDP) analogue, or combinations thereof. The adjuvant may be formulated in soluble form or in a nanoparticle, such as polylactic glycolic acid nanoparticles. A vaccine formulation comprises the adjuvant formulation and an immunogen. Methods of vaccinating an animal include delivering the vaccine formulation to the animal.
-
Paragraph 0054; 0090
(2020/06/10)
Active esters of formic acid as useful formylating agents: Improvements in the synthesis of formyl-amino acid esters, N-α-formyl-Met-Leu-Phe-OH, and formyl-Met-Lys-Pro-Arg, a phagocytosis stimulating peptide
-
Martinez,Laur
p. 979 - 981
(2007/10/02)
More Articles about upstream products of 70637-32-0